Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 5:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 831 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dyskinetic Syndrome Clear all
Completed Not applicable Interventional

Strength Training and Medication Effects in Parkinson Disease Effects on Hypokinesia in Parkinson Disease

NCT00665184
View directory record Official record
Conditions
Parkinson Disease
Interventions
Resistance Exercise via Negative Eccentric Work, Standard care exercise training
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
40 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Sep 9, 2026, 5:50 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biomarkers in Friedreich's Ataxia

NCT02497534
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
6 Years to 70 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 9, 2026, 5:50 PM EDT
Not listed Phase 2 Interventional

Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin

NCT02696044
View directory record Official record
Conditions
Rett Syndrome
Interventions
triheptanoin
Drug
Lead sponsor
Center for Rare Neurological Diseases, Norcross, GA
Other
Eligibility
2 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Norcross, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 9, 2026, 5:50 PM EDT
Completed No phase listed Observational

Memory Disorders Registry

NCT00654563
View directory record Official record
Conditions
Dementia, Alzheimer's Disease, Parkinson Disease, Huntington Disease
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Sep 9, 2026, 5:50 PM EDT
Not yet recruiting Phase 2 Interventional

DaxibotulinumtoxinA for Blepharospasm

NCT07489430
View directory record Official record
Conditions
Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid, Blepharospasm, Benign Essential, Blepharospasm
Interventions
Botulinum Neurotoxin Type A
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 9, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children

NCT00857727
View directory record Official record
Conditions
Agitation, Anesthesia, Pediatrics
Interventions
Dexmedetomidine, Saline
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
6 Months to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Sep 9, 2026, 5:50 PM EDT
Completed Phase 2 Interventional

Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01173731
View directory record Official record
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Levodopa
Interventions
AFQ056
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 9, 2026, 5:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Can Short Latency Afferent Inhibition Give us Clues to Better DYT 1 Dystonia Treatments?

NCT01435681
View directory record Official record
Conditions
DYT-1, DYT1, DYT 1, Dystonia
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
10 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Sep 9, 2026, 5:50 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension of EryDex Study IEDAT-04-2022

NCT06664853
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
Dexamethasone sodium phosphate
Drug
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Baltimore, Maryland • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 9, 2026, 5:50 PM EDT
Completed Not applicable Interventional Results available

rTMS and Botulinum Toxin in Primary Cervical Dystonia

NCT02542839
View directory record Official record
Conditions
Primary Cervical Dystonia, Dystonia
Interventions
NeuroStar TMS therapy, Sham NeuroStar TMS therapy, Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), Craniocervical Dystonia Questionnaire (CDQ-24), Cerebellar-brain Inhibition (CBI), Botulinum toxin injections
Device · Other · Procedure
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 9, 2026, 5:50 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

NCT06792500
View directory record Official record
Conditions
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Interventions
Glycerol Tributyrate
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 9, 2026, 5:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease

NCT00670709
View directory record Official record
Conditions
Huntington's Disease
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 9, 2026, 5:50 PM EDT
Withdrawn Phase 4 Interventional

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

NCT00786318
View directory record Official record
Conditions
Psychosis, Agitation, Delirium
Interventions
ziprasidone, Standard therapy
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 9, 2026, 5:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Electrophysiological Study of the Effects of Limb Cooling on Essential Tremor

NCT01093027
View directory record Official record
Conditions
Tremor
Interventions
15 - 30, 30 - 15
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Sep 9, 2026, 5:50 PM EDT
Recruiting Phase 1 Interventional

Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

NCT06554288
View directory record Official record
Conditions
Pediatric Disorder, Genetic Predisposition, Dystonia, Secondary, Dystonia, Cerebral Palsy, Dystonic-Rigid, Cerebral Palsy, Dyskinetic, Trihexyphenidyl Adverse Reaction, Pharmacogenomic Drug Interaction
Interventions
Trihexyphenidyl
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 9, 2026, 5:50 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

NCT06892288
View directory record Official record
Conditions
Phosphomannomutase 2 Deficiency, PMM2-CDG
Interventions
GLM101 (Part A, Double-blind), Placebo (Part A, Double-blind), GLM101 (Part B, Open-label)
Drug
Lead sponsor
Glycomine, Inc.
Industry
Eligibility
4 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Minneapolis, Minnesota • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 9, 2026, 5:50 PM EDT
Enrolling by invitation Not applicable Interventional

Effects of Stimulation Patterns of Deep Brain Stimulation

NCT02553525
View directory record Official record
Conditions
Parkinson Disease, Essential Tremor, Multiple Sclerosis, Dystonia
Interventions
Therapeutic Stimulation Patterns, Symptogenic Stimulation Patterns
Procedure
Lead sponsor
Duke University
Other
Eligibility
21 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Gainesville, Florida • Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 9, 2026, 5:50 PM EDT
Completed Not applicable Interventional

Physical and Mental Practice for Bimanual Coordination Rehabilitation

NCT03817086
View directory record Official record
Conditions
Traumatic Brain Injury, Weakness, Muscle, Coordination Impairment
Interventions
Hand coordination and mental practice, Hand coordination and action observation
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
20 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 9, 2026, 5:50 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

NCT01767129
View directory record Official record
Conditions
Dyskinesia, Parkinson's Disease
Interventions
AVP-923-45, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 9, 2026, 5:50 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa

NCT00134966
View directory record Official record
Conditions
Parkinson's Disease
Interventions
capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
Drug
Lead sponsor
Novartis
Industry
Eligibility
30 Years to 80 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
17
States / cities
Phoenix, Arizona • La Jolla, California • Reseda, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 9, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis

NCT05945615
View directory record Official record
Conditions
Blepharoptosis, Synkinesis, Hyperkinesis, Facial Paralysis
Interventions
Oxymetazoline 0.1% (Pf) Oph Soln Ud, Preservative free lubricating drops
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 9, 2026, 5:50 PM EDT
Completed No phase listed Observational

The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease

NCT01329536
View directory record Official record
Conditions
Alzheimer's Disease, Agitation
Interventions
Not listed
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Sep 9, 2026, 5:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sensory Symptoms in Tourette Syndrome and Obsessive-Compulsive Disorder

NCT04335175
View directory record Official record
Conditions
Tourette Syndrome, Obsessive-Compulsive Disorder, Sensory Disorders
Interventions
None - observational study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 9, 2026, 5:50 PM EDT
Not listed Not applicable Interventional

PHysical Activity and Exercise Outcomes in Huntington's Disease

NCT03344601
View directory record Official record
Conditions
Huntington Disease
Interventions
physical activity
Behavioral
Lead sponsor
Cardiff University
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Sep 9, 2026, 5:50 PM EDT